title: State of the art: using natriuretic peptide levels in clinical practice.
abstract: Natriuretic peptide (NP) levels (B-type natriuretic peptide (BNP) and N-terminal proBNP) are now widely used in clinical practice and cardiovascular research throughout the world and have been incorporated into most national and international cardiovascular guidelines for heart failure. The role of NP levels in state-of-the-art clinical practice is evolving rapidly. This paper reviews and highlights ten key messages to clinicians: 1) NP levels are quantitative plasma biomarkers of heart failure (HF). 2) NP levels are accurate in the diagnosis of HF. 3) NP levels may help risk stratify emergency department (ED) patients with regard to the need for hospital admission or direct ED discharge. 4) NP levels help improve patient management and reduce total treatment costs in patients with acute dyspnoea. 5) NP levels at the time of admission are powerful predictors of outcome in predicting death and re-hospitalisation in HF patients. 6) NP levels at discharge aid in risk stratification of the HF patient. 7) NP-guided therapy may improve morbidity and/or mortality in chronic HF. 8) The combination of NP levels together with symptoms, signs and weight gain assists in the assessment of clinical decompensation in HF. 9) NP levels can accelerate accurate diagnosis of heart failure presenting in primary care. 10) NP levels may be helpful to screen for asymptomatic left ventricular dysfunction in high-risk patients.
authors.affiliation: VA San Diego Healthcare System Cardiology, San Diego, CA 92161, USA. amaisel@ucsd.edu
authors.forename: Alan
authors.initials: A
authors.lastname: Maisel
authors.forename: Christian
authors.initials: C
authors.lastname: Mueller
authors.forename: Kirkwood
authors.initials: K
authors.lastname: Adams
authors.forename: Stefan D
authors.initials: SD
authors.lastname: Anker
authors.forename: Nadia
authors.initials: N
authors.lastname: Aspromonte
authors.forename: John G F
authors.initials: JG
authors.lastname: Cleland
authors.forename: Alain
authors.initials: A
authors.lastname: Cohen-Solal
authors.forename: Ulf
authors.initials: U
authors.lastname: Dahlstrom
authors.forename: Anthony
authors.initials: A
authors.lastname: DeMaria
authors.forename: Salvatore
authors.initials: S
authors.lastname: Di Somma
authors.forename: Gerasimos S
authors.initials: GS
authors.lastname: Filippatos
authors.forename: Gregg C
authors.initials: GC
authors.lastname: Fonarow
authors.forename: Patrick
authors.initials: P
authors.lastname: Jourdain
authors.forename: Michel
authors.initials: M
authors.lastname: Komajda
authors.forename: Peter P
authors.initials: PP
authors.lastname: Liu
authors.forename: Theresa
authors.initials: T
authors.lastname: McDonagh
authors.forename: Kenneth
authors.initials: K
authors.lastname: McDonald
authors.forename: Alexandre
authors.initials: A
authors.lastname: Mebazaa
authors.forename: Markku S
authors.initials: MS
authors.lastname: Nieminen
authors.forename: W Frank
authors.initials: WF
authors.lastname: Peacock
authors.forename: Marco
authors.initials: M
authors.lastname: Tubaro
authors.forename: Roberto
authors.initials: R
authors.lastname: Valle
authors.forename: Marc
authors.initials: M
authors.lastname: Vanderhyden
authors.forename: Clyde W
authors.initials: CW
authors.lastname: Yancy
authors.forename: Faiez
authors.initials: F
authors.lastname: Zannad
authors.forename: Eugene
authors.initials: E
authors.lastname: Braunwald